A recent study by researchers at the National Institutes of Health (NIH) has revealed a novel opioid compound that shows promise for effective pain relief without the typical risks associated with opioid use, potentially transforming pain management therapies and addressing opioid use disorder.
Researchers at the National Institutes of Health (NIH) have announced a significant breakthrough in opioid research with the discovery of a new opioid compound that demonstrates strong analgesic properties while significantly mitigating the risks commonly associated with opioid medications. Published in the journal Nature, the study highlights a compound that provides effective pain relief without the adverse effects of respiratory depression and the development of tolerance, which are major concerns in the ongoing opioid crisis.
Dr. Nora D. Volkow, director of the NIH’s National Institute on Drug Abuse (NIDA), emphasized the potential implications of this research for public health, stating, “Opioid pain medications are essential for medical purposes but can lead to addiction and overdose. Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.” This comment underscores the urgent need for safer alternatives in pain management, especially given the high rates of opioid addiction and overdose deaths in the United States.
Revisiting a Forgotten Class of Opioids
The researchers focused on a class of synthetic opioids known as nitazenes, which have not been extensively studied since the 1950s due to their extreme potency. Historically, these compounds were largely abandoned because of their associated risks, but the current study aimed to revisit them with a renewed focus on safety and efficacy. By modifying the compounds to enhance their therapeutic profiles, the researchers sought to retain their beneficial effects while minimizing potential dangers.
Michael Michaelides, Ph.D., a senior author of the study and investigator at NIDA, explained the research approach: “Our goal was to study the profile, or pharmacology, of these drugs. We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations.” This focused approach reflects a growing trend in pharmaceutical research to find effective medications that can alleviate pain without the high risks associated with traditional opioids.
The study began with the examination of a compound labeled FNZ, which was tracked using positron emission tomography (PET) imaging technology. PET allowed the researchers to observe the drug’s movement through the brain in real time. They discovered that while FNZ remained in the brain for only a brief period of five to ten minutes, its pain-relieving effects lasted for at least two hours, suggesting a potential for effective pain management through short-acting formulations.
Uncovering DFNZ: A Safer Option
During their research, the team identified DFNZ, a breakdown product of FNZ characterized as a “superagonist” due to its notably high activity at the mu opioid receptor, a key receptor implicated in opioid action. Although FNZ poses significant risks, including respiratory suppression and a high potential for addiction, DFNZ appears to circumvent many of these issues. At therapeutic doses, DFNZ was shown to increase brain oxygen levels steadily without hindering respiration, a critical factor in opioid safety.
Furthermore, repeated doses of DFNZ did not lead to tolerance, dependence, or severe withdrawal symptoms. Among the 14 standard signs of opioid withdrawal assessed, only mild irritability was noted in rats administered DFNZ, which is a promising indicator of its reduced addictive potential.
The researchers also conducted behavioral tests to further understand DFNZ’s addictive potential. In these tests, rats trained to press a lever to receive DFNZ demonstrated some self-administration behavior, implying rewarding effects. However, when DFNZ was substituted with saline, the rats quickly ceased seeking the drug, contrasting sharply with typical behaviors seen with substances like heroin and morphine, where subjects often continue to seek the drug even after it is no longer available.
Further analysis revealed that DFNZ promotes a slow and sustained release of dopamine in the brain’s reward pathways, without producing the sharp spikes in dopamine levels that are typically associated with powerful cravings and drug-seeking behavior. This characteristic could represent a significant advancement in the development of opioids that provide pain relief without the high risk of addiction.
Implications for Treatment and Future Investigations
The findings from this research challenge long-standing beliefs regarding the safety of highly active mu opioid receptor agonists in the context of pain management. The researchers propose that DFNZ not only has the potential to serve as an effective pain reliever but may also provide a new avenue for treating opioid use disorder, presenting advantages over current opioid-based therapies that still pose risks of respiratory depression.
Looking ahead, the research team plans to continue their preclinical studies to facilitate regulatory approval for human trials. They believe DFNZ could significantly benefit patients undergoing surgical procedures as well as those suffering from cancer-related or chronic pain, where effective and reliable pain management is crucial for quality of life.
This research represents a notable step forward in the quest to balance effective pain management with the need to minimize addiction and overdose risks. As the opioid epidemic remains a pressing public health crisis, the development of safer therapeutic options such as DFNZ could play a pivotal role in reshaping pain management practices in the future.
The study, titled “A µ-opioid receptor superagonist analgesic with minimal adverse effects,” was published on April 1, 2026, in Nature. The research received support from the NIH Intramural Research Program and an NIH/NIDA grant (DA056354).
No Comment! Be the first one.